Salivary Gland Tumor
Conditions
Brief summary
The goal of this study is to use advanced Magnetic Resonance Imaging (MRI) techniques to help identify the difference between cancerous and non-cancerous salivary gland tumors for improving treatment strategies and to aid in the prediction of disease progression.
Detailed description
The goal of this proposed study is to investigate the potential utility of combined analysis of parameters (Ktrans, ti and ADC) in discriminating benign from malignant salivary glands tumors (SGTs). A total of 30 treatment naïve patients suspicious of SGT as observed on clinical evaluation and prior routine CT, MRI, Ultrasound, FNAC and/or PET will undergo 3T MRI. The MRI protocol will include acquisition of anatomical images with and without contrast agent injection, diffusion imaging and dynamic contrast enhanced-MRI.
Interventions
DIAGNOSTIC_TESTMRI
You are being asked to complete one research MRI scan with and without contrast since your most recent clinical evaluation and/or prior imaging has shown the presence of a suspicious salivary gland tumor, prior to your scheduled upcoming surgery. MRI contrast agents act like a dye to make MRI pictures brighter and easier to read. During each MRI scan, you will have an intravenous line (IV line) placed. The IV line allows the contrast agent to be injected into your vein. If you have a history of renal disease you may be asked to complete a blood draw of approximately 2.5cc (½ teaspoon), for glomerular filtration rate (GFR) assessment for participation into the study.
Sponsors
McCabe Fund
Abramson Cancer Center at Penn Medicine
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Possess a salivary gland lesion of 1cm3 size * Have no prior history of treatment for salivary gland lesion
Exclusion criteria
* Has any prior history of cancer other than SGT * Has any MRI contra-indications * Has a history of known renal disease. * Has history of prior radiation to head and neck region * Is pregnant
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Differentiation and Progression Free | 6 Month after the end of treatment | Differentiation of malignant from benign neoplasms and progression free survival at 6 month starting from end of chemo-radiation treatment |
Countries
United States
Contacts
Primary ContactMarisa Sanchez
Backup ContactLisa Desiderio
Outcome results
None listed